World Sickle Cell Day 2016 : A time for appraisal

Before the end of the Stroke Prevention Trial in Sickle Cell Anemia (STOP) in 1998, approximately 11 per cent of children with SCD in high-income countries developed a stroke [14] . Since implementation of TCD screening, overt stroke occurred in just one per cent of these children [15] . [...]implem...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of medical research (New Delhi, India : 1994) India : 1994), 2016-06, Vol.143 (6), p.678-681
Main Authors: Thein, Mya, Thein, Swee
Format: Article
Language:English
Subjects:
Anemia, Sickle Cell - epidemiology
Anemia, Sickle Cell - pathology
Anemia, Sickle Cell - therapy
Blood transfusions
Care and treatment
Collaboration
Complications and side effects
Disease prevention
Distribution
FDA approval
Genetic aspects
High income
Humans
India
Medical screening
Mortality
Perceptions
Prevalence studies (Epidemiology)
Prevention
Research funding
Sickle cell anemia
Sickle cell disease
Stem cells
Stroke
World Health Organization
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Before the end of the Stroke Prevention Trial in Sickle Cell Anemia (STOP) in 1998, approximately 11 per cent of children with SCD in high-income countries developed a stroke [14] . Since implementation of TCD screening, overt stroke occurred in just one per cent of these children [15] . [...]implementation of TCD screening and preventive blood transfusion has significantly reduced the incidence of first stroke in children from 0.67/100 person-years before 1998 to 0.06/100 person-years after the implementation of this practice in the United States [16] . In years to come, the results from REACH (Realizing effectiveness cross continent with hydroxyurea) trial could help us answer an essential question of "How can we safely and effectively introduce the use of hydroxyurea in different regions of Africa? [19]" Blood transfusion is an effective treatment for the prevention and management of many acute and chronic complications, contributing to its increasing usage and transfusion-related complications. Implementation of the roadmap for reducing childhood mortality from SCD (as shown in high-income countries) is fraught with challenges in low-income settings from a combination of lack of political will and government strategies, limited resources, and lack of research infrastructure.
ISSN:0971-5916
DOI:10.4103/0971-5916.191917